
HUTCHMED reports positive preclinical results for HMPL-A830 cancer candidate
Key points
- HUTCHMED reported encouraging preclinical findings for HMPL-A830, an experimental cancer treatment combining an EGFR-targeting antibody with a KRAS inhibitor, at the EORTC-NCI-AACR cancer therapeutics conference.
- The KRAS inhibitor demonstrated activity across 55 tumour cell lines with different KRAS alterations and produced more durable tumour regressions than KRAS G12C inhibitors in certain mouse models.
- HMPL-A830 is being evaluated in an ongoing global Phase I trial involving patients with advanced solid tumours, while a GSK subsidiary holds exclusive development and commercialisation rights outside specified Asian territories.
HUTCHMED (NASDAQ:AIM:HCM) reported positive preclinical results for HMPL-A830, an experimental cancer treatment designed to target EGFR and KRAS signalling, at the 38th EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics in Barcelona.
HMPL-A830 is a first-in-class antibody-targeted therapy conjugate (ATTC) that combines an EGFR-targeting antibody with a potent KRAS inhibitor payload.
The treatment is designed to deliver the inhibitor directly to EGFR-expressing tumour cells while simultaneously blocking EGFR and KRAS signalling.
Laboratory testing showed that the KRAS inhibitor blocked both active and inactive states of the protein and demonstrated antiproliferative activity across 55 tumour cell lines with different KRAS alterations, including G12C, G12D, G12V and G13D mutations. Activity was also observed in models involving amplification of wild-type KRAS.
In mouse models involving EGFR-positive tumours with KRAS alterations, HMPL-A830 demonstrated dose-dependent antitumour activity and produced more durable tumour regressions than KRAS G12C inhibitors.
The candidate also outperformed several other treatment approaches evaluated in the preclinical comparisons.
The findings also showed rapid uptake into EGFR-positive cells, activity against neighbouring EGFR-negative tumour cells and sustained inhibition of downstream EGFR/KRAS signalling.
The drug-to-antibody ratio remained stable in mouse, monkey and human plasma in preclinical analyses.
HMPL-A830 is currently being evaluated in the Phase Ia portion of an ongoing global Phase I clinical trial involving patients with unresectable, advanced or metastatic solid tumours.
The first patient received treatment in China on September 24, 2026, with the study assessing safety, tolerability, pharmacokinetics and preliminary antitumour activity.
Under an exclusive licensing agreement that closed on October 21, 2026, a GSK subsidiary obtained worldwide development and commercialisation rights outside Mainland China, Hong Kong, Macau and Taiwan.
HUTCHMED retains responsibility for global Phase I development, while GSK will lead subsequent clinical development and commercialisation in its licensed territories.
The agreement includes a $110 million upfront payment, potential additional development, regulatory and commercial milestone payments of up to $1.185 billion, and tiered royalties on annual net sales.
Frequently asked questions
More from United States
Youdao revenue slides 12.3% to RMB1.4 billion in Q3
NetEase revenue falls 1.8% to RMB27.9 billion
Futu quarterly revenue increases 4.5% to HK$6.69 billion
Sunlands revenue falls 36.6% to RMB331.6 million
ATRenew revenue jumps 25.3% to RMB6.45 billion
Oil prices steady as supply surplus outlook offsets Middle East tensions



